New Abbott data revealed at meeting
LIBERTYVILLE TOWNSHIP -- Two studies show that in patients with multiple lipid problems, Abbott's ABT-335 combined with two commonly prescribed statins significantly improved three key lipids -- LDL "bad" cholesterol, triglycerides and HDL "good" cholesterol -- compared to the corresponding monotherapies. Results were presented Monday at the American College of Cardiology's 57th annual Scientific Sessions in Chicago. ABT-335, an investigational new fenofibric acid molecule, will be known as TriLipix.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.